Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-3 adjunctive trial, demonstrating a statistically significant increase in total “on” time without troublesome dyskinesia compared with placebo over 27 weeks
Results demonstrate tavapadon’s potential to provide the right balance of motor control, safety and tolerability for people living with Parkinson’s disease
Additional data from the trial will be presented at a future medical meeting; results from the tavapadon Phase 3 monotherapy trials (TEMPO-1 and TEMPO-2) are expected in the second half of 2024
About Tavapadon
Tavapadon is the first and only selective D1/D5 receptor partial agonist in development for Parkinson’s disease and is currently being studied as a once-daily medicine for use as both a monotherapy and as an adjunctive therapy to LD. Tavapadon is designed to selectively and optimally activate D1/D5 receptors to potentially provide the right balance of motor control, safety and tolerability for patients. By selectively activating D1/D5 dopamine receptors along the nigrostriatal pathway, tavapadon has the potential to offer the right balance of dopamine signaling to improve motor control while avoiding D2/D3 overstimulation, which is believed to underlie many of the side effects of current dopamine agonists. Additionally, as a partial agonist with a 24-hour half-life enabling once-daily dosing, tavapadon may avoid hyperactivation of the dopamine receptors, which can lead to troublesome dyskinesias.
Written by
nednedned
To view profiles and participate in discussions please or .
"Dopamine receptors are expressed in the central nervous system, specifically in the hippocampal dentate gyrus and subventricular zone. Dopamine receptors are also expressed in the periphery, more prominently in the kidney and vasculature,
There are five types of dopamine receptors, which include D1, D2, D3, D4, and D5. Each receptor has a different function and is found in different locations.
The function of each dopamine receptor[4]:
D1: memory, attention, impulse control, regulation of renal function, locomotion
For those with an interest in investing, Cerevel is being bought out by Abbvie for cash. Abbvie is huge, so there is no investment play here in my opinion.
This is great news. I have talked to someone who was a VP at Cerevel and participated in the development of Tavapadon. It could be a really substantial change in treatment instead of C/L.
The current agonists that were developed in the 90s would not meet the standards of this testing procedure. They have shown insufficient results and have too many side effects. However, due to the lack of better options, they are still being prescribed. It is hopeful that safe and effective alternatives will become available in the “near future." 👍
Thanks for sharing this! It sounds really encouraging!What an exciting time we live in, to be on the edge of newly discovered treatments that can make a real difference for all of us!
I don't get too excited about many of the things I read in possible new treatments.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
Benfotiamine In The Mix For PD Again? 
Weight Loss, in a positive way
Potential disease-modifying therapy enters Phase 2
